Single User License
INR 129300
Site License
INR 258600
Corporate User License
INR 387900

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Secondary Hyperparathyroidism-Pipeline Review, H2 2015

Secondary Hyperparathyroidism-Pipeline Review, H2 2015


  • Products Id :- GMDHC6996IDB
  • |
  • Pages: 65
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Secondary Hyperparathyroidism-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Secondary Hyperparathyroidism-Pipeline Review, H2 2015', provides an overview of the Secondary Hyperparathyroidism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Secondary Hyperparathyroidism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Secondary Hyperparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Secondary Hyperparathyroidism Overview 7

Therapeutics Development 8

Pipeline Products for Secondary Hyperparathyroidism-Overview 8

Pipeline Products for Secondary Hyperparathyroidism-Comparative Analysis 9

Secondary Hyperparathyroidism-Therapeutics under Development by Companies 10

Secondary Hyperparathyroidism-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Secondary Hyperparathyroidism-Products under Development by Companies 14

Secondary Hyperparathyroidism-Companies Involved in Therapeutics Development 15

Amgen Inc. 15

Deltanoid Pharmaceuticals Inc. 16

Mitsubishi Tanabe Pharma Corporation 17

Nektar Therapeutics 18

OPKO Health, Inc. 19

Secondary Hyperparathyroidism-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

Calcifediol MR-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Calcimimetic-18-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CTA-091-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

CTAP-201-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

DP-001-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

etelcalcetide-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

lunacalcipol-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

MT-4580-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NKTR-228-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

VS-105-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

VS-110-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

VS-411-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Secondary Hyperparathyroidism-Recent Pipeline Updates 46

Secondary Hyperparathyroidism-Dormant Projects 55

Secondary Hyperparathyroidism-Dormant Projects 55

Secondary Hyperparathyroidism-Discontinued Products 56

Secondary Hyperparathyroidism-Product Development Milestones 57

Featured News & Press Releases 57

Jul 28, 2015: FDA Accepts OPKO's New Drug Application for Rayaldee 57

May 29, 2015: OPKO Announces Submission of Rayaldee New Drug Application to U.S. Food and Drug Administration 57

May 29, 2015: Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 57

Mar 27, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings 59

Mar 06, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference 59

Feb 25, 2015: Amgen Announces Positive Results from Head-To-Head Study Comparing the Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 59

Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis 60

Sep 23, 2014: OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints 61

Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan 62

Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H2 2015 8

Number of Products under Development for Secondary Hyperparathyroidism-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Secondary Hyperparathyroidism-Pipeline by Amgen Inc., H2 2015 15

Secondary Hyperparathyroidism-Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015 16

Secondary Hyperparathyroidism-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 17

Secondary Hyperparathyroidism-Pipeline by Nektar Therapeutics, H2 2015 18

Secondary Hyperparathyroidism-Pipeline by OPKO Health, Inc., H2 2015 19

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Mechanism of Action, H2 2015 24

Number of Products by Stage and Route of Administration, H2 2015 26

Number of Products by Stage and Molecule Type, H2 2015 28

Secondary Hyperparathyroidism Therapeutics-Recent Pipeline Updates, H2 2015 46

Secondary Hyperparathyroidism-Dormant Projects, H2 2015 55

Secondary Hyperparathyroidism-Discontinued Products, H2 2015 56

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H2 2015 8

Number of Products under Development for Secondary Hyperparathyroidism-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Top 10 Targets, H2 2015 21

Number of Products by Stage and Top 10 Targets, H2 2015 21

Number of Products by Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Top 10 Routes of Administration, H2 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25

Number of Products by Top 10 Molecule Types, H2 2015 27

Number of Products by Stage and Top 10 Molecule Types, H2 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Deltanoid Pharmaceuticals Inc.

Mitsubishi Tanabe Pharma Corporation

Nektar Therapeutics

OPKO Health, Inc.

Secondary Hyperparathyroidism Therapeutic Products under Development, Key Players in Secondary Hyperparathyroidism Therapeutics, Secondary Hyperparathyroidism Pipeline Overview, Secondary Hyperparathyroidism Pipeline, Secondary Hyperparathyroidism Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com